By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516


SEARCH JOBS
Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

    Key Statistics


    Email: info@esperion.com
    Ownership: Public

    Web Site: Esperion
    Employees:
    Symbol: ESPR
     



  • Industry
    Biotechnology






    Company News
    Esperion (ESPR) Provides Update On The ETC-1002 Development Program Following End-Of-Phase II Meeting With FDA 8/18/2015 7:20:10 AM
    Esperion (ESPR) Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval 8/18/2015 6:35:11 AM
    Esperion Therapeutics (ESPR) Provides ETC-1002 Development Program Update; Reports Second Quarter 2015 Financial Results 8/7/2015 2:01:14 PM
    Esperion Therapeutics (ESPR) To Provide Second Quarter Program Updates And Financial Results 7/29/2015 9:26:16 AM
    Esperion Therapeutics (ESPR) Announces Positive Top-Line Phase 2 Results For ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/28/2015 9:39:48 AM
    Esperion Therapeutics (ESPR) To Host Second Annual Analyst And Investor Day 7/23/2015 3:20:46 PM
    Esperion Therapeutics (ESPR) Announces Removal Of 240 mg Partial Clinical Hold For ETC-1002 7/7/2015 9:32:50 AM
    Esperion Therapeutics (ESPR) To Present At The JMP Securities Life Science Conference 6/17/2015 8:52:59 AM
    Esperion Therapeutics (ESPR) Announces The Appointment Of Scott Braunstein, M.D. To Board Of Directors 6/15/2015 10:42:00 AM
    Esperion Therapeutics (ESPR) Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results 5/8/2015 8:34:27 AM
    12345678910...
    //-->